Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232336 · ClinicalTrials.gov registry record · Phase 4
Quetiapine for Cocaine Use and Cravings
A Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT00232336: Completed Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT00232336 is a Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 42 participants, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00232336, a Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to collect pilot data on whether quetiapine may be effective in the reduction of cocaine use and cravings in cocaine dependent individuals.
Conditions Studied
Interventions
- DRUG quetiapine
Study Locations (1)
Washington
- VA Puget Sound Health Care System, American Lake Division - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
What the finished NCT00232336 record still lists
NCT00232336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which quetiapine is the first listed.
NCT00232336 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00232336 about?
NCT00232336 is a clinical study titled "Quetiapine for Cocaine Use and Cravings". The purpose of this study was to collect pilot data on whether quetiapine may be effective in the reduction of cocaine use and cravings in cocaine dependent individuals.
What is the current status of trial NCT00232336?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2003-10. Estimated completion is 2006-01.
What conditions does trial NCT00232336 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Cocaine-Related Disorders.
What interventions are being tested in trial NCT00232336?
The interventions under investigation include: quetiapine (DRUG).
Who is sponsoring clinical trial NCT00232336?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00232336 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00232336's enrollment target sits among peer trials
42 47th of 58 higher than 12 of 58 other Substance-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modeling Impaired Judgement in Cocaine Abusers - 6
COMPLETED · Phase 4
-
Relapse Prevention With Varenicline
COMPLETED · Phase 4
-
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
COMPLETED · Phase 4
-
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia